在FDA的压力之下,2010年10月,雅培制药公司同意自发地撤回美国市场的“诺美婷”。
Under pressure from the FDA, Abbott Laboratories agreed to voluntarily withdraw Meridia from the U. S. market on October 8, 2010.
失败的例子比比皆是:诺美婷(心脏病、中风),芬-芬(心脏危险),利莫那班(自杀倾向),麻黄(心脏病、中风)。
The weight-loss busts are plenty: Meridia (heart attacks, strokes), Fen-phen (heart risk), Rimonabant (suicidal thoughts), ephedra (heart attacks, strokes).
应用推荐